Delivery of engineered extracellular vesicles with miR-29b editing system for muscle atrophy therapy

J Nanobiotechnology. 2022 Jun 27;20(1):304. doi: 10.1186/s12951-022-01508-4.


Muscle atrophy is a frequently observed complication, characterized by the loss of muscle mass and strength, which diminishes the quality of life and survival. No effective therapy except exercise is currently available. In our previous study, repressing miR-29b has been shown to reduce muscle atrophy. In our current study, we have constructed artificially engineered extracellular vesicles for the delivery of CRISPR/Cas9 to target miR-29b (EVs-Cas9-29b). EVs-Cas9-29b has shown a favorable functional effect with respect to miR-29b repression in a specific and rapid manner by gene editing. In in vitro conditions, EVs-Cas9-29b could protect against muscle atrophy induced by dexamethasone (Dex), angiotensin II (AngII), and tumor necrosis factor-alpha (TNF-α). And EVs-Cas9-29b introduced in vivo preserved muscle function in the well-established immobilization and denervation-induced muscle atrophy mice model. Our work demonstrates an engineered extracellular vesicles delivery of the miR-29b editing system, which could be potentially used for muscle atrophy therapy.

Keywords: CRISPR/Cas9; Engineered extracellular vesicles; Muscle atrophy; Therapy; miR-29b.

MeSH terms

  • Animals
  • CRISPR-Cas Systems
  • Extracellular Vesicles*
  • Mice
  • MicroRNAs* / genetics
  • Muscular Atrophy* / genetics
  • Muscular Atrophy* / therapy
  • Tumor Necrosis Factor-alpha


  • MIRN29 microRNA, mouse
  • MicroRNAs
  • Tumor Necrosis Factor-alpha